Tag: biosimilars

Generic drugs make up 90% of U.S. prescriptions but only 12% of spending. Why do patients still doubt them? Learn how transparency, supply chains, and education are changing perceptions - and why trust, not price, is the future of generic medicine.

Authorized biologic alternatives, or biosimilars, are highly similar versions of complex biologic drugs that offer major cost savings without compromising safety. Unlike generics, they’re not exact copies-but they work just as well.

Lot-to-lot variability is a natural part of biologics and biosimilars due to their complex, cell-based manufacturing. Learn how regulators ensure safety, why biosimilars aren't generics, and what this means for patients and labs.